Indivior Pharmaceuticals, Inc. INDV Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $89M+89.4% | $102M+386% | $42M+90.9% | $18M+119% | $47M-23.0% | ||
| $2M-33.3% | $2M-60.0% | $3M-25.0% | $2M0.0% | $3M-40.0% | ||
| $9M+50.0% | $5M-16.7% | $7M+16.7% | $8M+33.3% | $6M0.0% | ||
| $27M+1,450% | -$38M-203% | -$15M-150% | $9M+133% | -$2M-167% | ||
| $6M— | $3M— | $16M— | $0-100% | $0-100% | ||
| $20M+282% | -$6M-250% | $18M+300% | -$4M-140% | -$11M-175% | ||
| $1M+120% | -$2M-200% | —— | -$17M-313% | -$5M-119% | ||
| $18M0.0% | -$11M— | -$7M— | -$49M— | $18M+105% | ||
| -$86M-206% | —— | —— | $50M-18.0% | $81M— | ||
| $0+100% | —— | -$1M— | —— | -$1M0.0% | ||
| $2M0.0% | $3M-25.0% | $2M-50.0% | $3M— | $2M— | ||
| -$18M— | —— | —— | —— | $0— | ||
| -$9M-112% | -$221M— | -$39M-2,050% | $158M+79.5% | $75M+303% | ||
| $20M+300% | $24M+50.0% | $20M+186% | $17M+325% | $5M+150% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $6M0.0% | $5M-82.8% | $3M-93.5% | $5M-54.5% | $6M-80.6% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $5M0.0% | $6M+100% | $3M-40.0% | $6M+20.0% | $5M+25.0% | ||
| -$19M-280% | -$24M-400% | -$20M-157% | -$17M-1,800% | -$5M-120% | ||
| $126M+1,045% | —— | —— | —— | $11M-69.4% | ||
| $489M— | —— | —— | —— | $0-100% | ||
| $333M+8,225% | $5M-97.9% | $4M+300% | $4M— | $4M+300% | ||
| $0-100% | —— | $1M0.0% | —— | $1M-50.0% | ||
| $21M+600% | $2M0.0% | —— | —— | $3M-85.0% | ||
| $3M— | —— | —— | $0— | $0+100% | ||
| $5M— | —— | —— | —— | $0-100% | ||
| $7M+141% | -$5M— | -$3M+94.1% | -$5M+85.7% | -$17M+69.6% | ||
| $0— | $0-100% | -$2M-100% | $1M— | $0— | ||
| -$20M-138% | -$252M-913% | -$61M-336% | $136M+152% | $53M+178% | ||
| $6M— | $3M— | $16M— | $0-100% | $0-100% | ||
| $0-100% | -$3M-160% | -$3M0.0% | $4M+500% | $1M0.0% | ||
| -$38M+38.7% | -$310M-6,100% | —— | —— | -$62M+87.2% | ||
| $18M0.0% | -$11M— | -$7M— | -$49M— | $18M+105% | ||
| $2M0.0% | $3M-25.0% | $2M-50.0% | $3M— | $2M— | ||
| $0+100% | —— | -$1M— | —— | -$1M0.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $5M0.0% | $6M+100% | $3M-40.0% | $6M+20.0% | $5M+25.0% | ||
| —— | $250K— | $250K— | $250K— | $250K— | ||
| $5M— | —— | —— | —— | $0-100% | ||
| $3M— | —— | —— | $0— | $0+100% | ||
| $0— | $0-100% | -$2M-100% | $1M— | $0— | ||
| -$29M-141% | -$245M— | -$59M— | $141M+67.9% | $70M+279% | ||
| -$29M-141% | -$245M— | -$59M— | $141M+67.9% | $70M+279% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.